Over 900 development projects in the pipeline

The competition to be the first generic on the market after patent expiry is fierce. Achieving that coveted number one slot is preceded by many years of development work and negotiation with regulatory authorities, and also involves an intricate journey through the complicated patent network.

Sandoz has built up a comprehensive global production and development network with competence centres in all major markets in order to expand its activities beyond commodity generics and to promote innovation. Spending on development has increased consistently over the years and, with more than 900 development projects in the pipeline, we have an unusually extensive pipeline for a generics manufacturer.

In addition to generic medicines, our expertise in biotechnology enables us to develop and produce complex and cost-effective biopharmaceutical medicines. With worldwide demand for these products increasing steadily, we are proud that Sandoz is a pioneer in the field of biosimilars.